Ankylosing Spondylitis Clinical Trial
Official title:
Comparison of the Benefit Experienced by Patients With Ankylosing Spondylitis, Under Biotherapy, During Management by an Adapted Physical Activity Compared to a Standard Treatment by Kinesitherapy.
The current management of Spondylarthritis Ankylosant (SA), according to the recommendations
of the HAS (High Authority of Health), must be a multidisciplinary global approach
coordinated by the rheumatologist combining a pharmacological aspect (NSAID, analgesics,
biotherapy ...) and not pharmacological (physical treatments, educational approaches, social
measures ...). The therapeutic aim of this management is to achieve a low level of activity
of the disease and a decrease of the repercussion of this one in the daily life of the
patient.
The standard physical treatment currently provided is physiotherapy. This can be prescribed
throughout the disease by the rheumatologist, adapted to the stage of AS and the clinical
condition of the patient. The medical teams note in their daily practice that there may be a
lack of attendance of patients at prescribed physiotherapy sessions. This has been confirmed
in research on certain chronic rheumatic diseases, including AS, for which patients became
less adherent to physical treatments and thus lost the expected benefits, particularly in
terms of the functional impact of AS in the patient's daily life. (BASFI). Various studies
have also shown that combining several physical activities (including aerobic and muscle
building) or / and performing them in groups at a regular frequency (three times a week)
could significantly improve several AS parameters, including BASFI.
From these different findings, we hypothesized that a multidisciplinary treatment combining a
"cardio training" with muscle strengthening, supervised by qualified sports coaches, for a
year, could reduce the impact of SA in the daily life of patients balanced by a biotherapy,
compared to standard physiotherapy. This original care is part of the Adapted Physical
Activity (APA), whose application decree came into force on March 1, 2017 and allows doctors
to prescribe a physical therapy tailored to the needs of the patient. At present, the APA
remains at the expense of the patients in ALD and in some cases, it can be supported,
partially or totally, by the complementary health. APA could therefore be an alternative and
/ or complementary to physiotherapy as a physical therapy in the management of AS, in
addition to pharmacological treatments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
| Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
| Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
| Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
| Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
| Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
| Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
| Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
| Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
| Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
| Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
| Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
| Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
| Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
| Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
| Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |